Floatz Rating
BB64/100
Confidence
Indicative
Sponsor
University of Washington
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
56High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT00880178CT.gov Plaque Inflammation and Dysfunctional HDL in AIM-HIGH | — | Completed | — | — | — |
NCT00120289CT.gov Niacin Plus Statin to Prevent Vascular Events | — | Terminated | — | — | — |
NCT00079638CT.gov Comparative Efficacy Evaluation of Lipids When Treated With Niaspan & Statin or Other Lipid-Modifying Therapies-COMPELL | — | Completed | — | — | — |
NCT00246376CT.gov Diet, Exercise, Niacin, and Fenofibrate to Reduce Heart Disease Risk Factors in Individuals With HIV Lipodystrophy or Dyslipidemia | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Atherosclerosis
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Niacin (this asset) | University of Washington | Approved | BB · 64 |
| Aspirin | Rajaie Cardiovascular Medical and Research Center | P4 | BBB |
| Simvastatin | Northern California Institute of Research and Education | P4 | BB |
| Atorvastatin | Erasmus Medical Center | P4 | BB |
| Cilostazol | Asan Medical Center | P4 | B |
| Clopidogrel | Ewha Womans University Seoul Hospital | P4 | B |
| Rosuvastatin | Emory University | P4 | B |
| Ezetimibe | paresh Dandona | P4 | B |
| Alteplase | Alexandria University | P4 | B |
+37 more in the Atherosclerosis cohort
Other indications for Niacin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Abdominal Obesity-Metabolic Syndrome | — | P4 | BB · 68 |
| Inherited Lipid Metabolism Disorder | — | P4 | BB · 68 |
| Coronary Artery Disorder | — | P4 | BB · 68 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Niacin in Atherosclerosis. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026. Accessed July 15, 2026. https://terminal.floatz.ai/assets/niacin-atherosclerosis
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →